SEEL (Seelos Therapeutics) Utang jangka cendhak marang modal

This chart illustrates that the market value of Seelos Therapeutics (SEEL) is 0.00. The business focuses on developing drugs for depression and CNS pathologies, where strict FDA oversight and patent law block competitors from entering the market. While the team attracts scientists with research freedom and stock options, management is currently fighting for survival due to a lack of funds and previous trial failures.

This ratio measures the proportion of short-term liabilities relative to equity, allowing investors to assess liquidity risk and dependence on borrowing costs; by analyzing short-term loans to the capital of Seelos Therapeutics (SEEL), it becomes evident how the lack of revenue from CNS clinical trials and rising pipeline costs leave Seelos Therapeutics (SEEL) vulnerable to any increase in the cost of servicing current debt.